What was filed
Aurobindo Pharma told the exchanges that its wholly owned subsidiary, Apitoria Pharma Private Limited, has completed the acquisition of the Contract Research Services business of the A1 Biochem Group, after the conditions set out in the definitive agreements were satisfied. The deal had been flagged in earlier intimations dated July 23, September 12, October 1 and October 2, 2026; this filing marks the closing.
Apitoria now holds an 80% stake in A1 Biochem Labs (India) Private Limited, with the balance retained by Dr. Rajendra Gadikota, the former promoter of the A1 Biochem Group. The India entity, in turn, holds the group's US operations: through its wholly owned subsidiary A1 Biochem USA Inc, it has acquired full membership interest in A1 Biochem Labs LLC, which operates in the United States.
The rationale stated
The company framed the acquisition as adding a contract research (CRO) platform to Apitoria's existing manufacturing base. Per the filing, the acquired business brings an established client base and a record of completed projects across India and the US.
Aurobindo said the move complements Apitoria's manufacturing capabilities to build an integrated CRDMO platform — contract research, development and manufacturing — and to broaden its offerings and deepen customer engagement over longer life cycles. The financial terms of the transaction were not disclosed in this filing.